Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $24,892.14 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 546 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $45.59, for a total transaction of $24,892.14. Following the sale, the chief executive officer now owns 672,518 shares in the company, valued at approximately $30,660,095.62. This trade represents a 0.08 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Twist Bioscience Trading Down 1.1 %

NASDAQ:TWST opened at $45.12 on Friday. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of -12.53 and a beta of 1.85. The firm’s fifty day simple moving average is $46.26 and its 200 day simple moving average is $46.47.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently modified their holdings of TWST. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience during the 3rd quarter worth approximately $43,992,000. Point72 Asset Management L.P. lifted its position in shares of Twist Bioscience by 1,021.8% during the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after purchasing an additional 613,057 shares in the last quarter. Fred Alger Management LLC lifted its position in shares of Twist Bioscience by 720.7% during the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after purchasing an additional 575,080 shares in the last quarter. State Street Corp boosted its stake in shares of Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the period. Finally, Wellington Management Group LLP grew its holdings in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after purchasing an additional 521,272 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have recently issued reports on TWST. Evercore ISI raised their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. TD Cowen reiterated a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Finally, Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.